Wolfe Research Cuts Ratings on Insmed and Roivant Sciences
Wolfe Research lowered its ratings on Insmed and Roivant Sciences from Outperform to Peer Perform, Dow Jones Newswires reported, citing Benzinga data.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Wolfe Research lowered its rating on Insmed from Outperform to Peer Perform on October 12, 2026. Dow Jones Newswires reported the action, citing analyst-ratings data from Benzinga.
The same recommendation change was made for Roivant Sciences on the same day, with its rating also reduced from Outperform to Peer Perform.
why it matters
Analyst-rating changes can affect investor attention toward Insmed and Roivant Sciences and shape market views of companies in the biotechnology sector.
instruments
sources
- Insmed Cut to Peer Perform From Outperform by Wolfe Research — Dow Jones Newswires, 12 October 2026 at 12:21 UTC
- Roivant Sciences Cut to Peer Perform From Outperform by Wolfe Research — Dow Jones Newswires, 12 October 2026 at 12:20 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗